Clinical Data Reported on Celgene Corporation Compound Apremilast (CC-10004) Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced that clinical data from a completed Phase II study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis were presented for the first time at the 66th American Academy of Dermatology meeting in San Antonio, Texas on Saturday, Feb. 2, 2008.